View Future GrowthBirzeit Pharmaceuticals 過去の業績過去 基準チェック /46Birzeit Pharmaceuticalsの収益は年間平均-1.1%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間8.1% 1%割合で 増加しています。 Birzeit Pharmaceuticalsの自己資本利益率は11%であり、純利益率は25.6%です。主要情報-1.13%収益成長率-1.16%EPS成長率Pharmaceuticals 業界の成長12.39%収益成長率1.02%株主資本利益率10.96%ネット・マージン25.58%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: US$0.038 (vs US$0.04 in 2Q 2023)Second quarter 2024 results: EPS: US$0.038 (down from US$0.04 in 2Q 2023). Revenue: US$8.36m (down 23% from 2Q 2023). Net income: US$1.48m (down 11% from 2Q 2023). Profit margin: 18% (up from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.Reported Earnings • Jun 13First quarter 2024 earnings released: US$0.04 loss per share (vs US$0.046 profit in 1Q 2023)First quarter 2024 results: US$0.04 loss per share (down from US$0.046 profit in 1Q 2023). Revenue: US$9.07m (down 11% from 1Q 2023). Net loss: US$1.44m (down 181% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.Reported Earnings • Feb 28Full year 2023 earnings released: EPS: US$0.16 (vs US$0.20 in FY 2022)Full year 2023 results: EPS: US$0.16 (down from US$0.20 in FY 2022). Revenue: US$43.1m (down 8.3% from FY 2022). Net income: US$6.12m (down 23% from FY 2022). Profit margin: 14% (down from 17% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.059 in 2Q 2022)Second quarter 2023 results: EPS: US$0.04 (down from US$0.059 in 2Q 2022). Revenue: US$10.9m (down 2.7% from 2Q 2022). Net income: US$1.67m (down 28% from 2Q 2022). Profit margin: 15% (down from 21% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.Reported Earnings • Aug 14Second quarter 2022 earnings released: EPS: US$0.063 (vs US$0.13 in 2Q 2021)Second quarter 2022 results: EPS: US$0.063 (down from US$0.13 in 2Q 2021). Revenue: US$11.2m (down 16% from 2Q 2021). Net income: US$2.30m (down 53% from 2Q 2021). Profit margin: 21% (down from 37% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year and the company’s share price has also increased by 18% per year.Reported Earnings • Feb 21Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$45.5m (up 27% from FY 2020). Net income: US$12.1m (up 64% from FY 2020). Profit margin: 27% (up from 21% in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 6% per year.すべての更新を表示Recent updatesBoard Change • Jun 02No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 5 highly experienced directors. No independent directors (8 non-independent directors). Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 5 highly experienced directors. No independent directors (8 non-independent directors). Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 10+ 1 more updateBirzeit Pharmaceuticals Company announces Annual dividend, payable on July 15, 2026Birzeit Pharmaceuticals Company announced Annual dividend of USD 0.0500 per share payable on July 15, 2026, ex-date on May 06, 2026 and record date on May 07, 2026.Board Change • Jun 10No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 25Birzeit Pharmaceuticals Company announces Annual dividend, payable on May 15, 2025Birzeit Pharmaceuticals Company announced Annual dividend of USD 0.0500 per share payable on May 15, 2025, ex-date on April 23, 2025 and record date on April 24, 2025.Board Change • Apr 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 09Birzeit Pharmaceuticals Company, Annual General Meeting, Apr 22, 2025Birzeit Pharmaceuticals Company, Annual General Meeting, Apr 22, 2025. Location: ramallah Palestinian AuthorityBoard Change • Feb 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Oct 29New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.7% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.8% net profit margin).Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: US$0.038 (vs US$0.04 in 2Q 2023)Second quarter 2024 results: EPS: US$0.038 (down from US$0.04 in 2Q 2023). Revenue: US$8.36m (down 23% from 2Q 2023). Net income: US$1.48m (down 11% from 2Q 2023). Profit margin: 18% (up from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.New Risk • Jun 13New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 39% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (4.9% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.9% net profit margin).Reported Earnings • Jun 13First quarter 2024 earnings released: US$0.04 loss per share (vs US$0.046 profit in 1Q 2023)First quarter 2024 results: US$0.04 loss per share (down from US$0.046 profit in 1Q 2023). Revenue: US$9.07m (down 11% from 1Q 2023). Net loss: US$1.44m (down 181% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.New Risk • Jun 11New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.0% average weekly change).Reported Earnings • Feb 28Full year 2023 earnings released: EPS: US$0.16 (vs US$0.20 in FY 2022)Full year 2023 results: EPS: US$0.16 (down from US$0.20 in FY 2022). Revenue: US$43.1m (down 8.3% from FY 2022). Net income: US$6.12m (down 23% from FY 2022). Profit margin: 14% (down from 17% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.Buy Or Sell Opportunity • Feb 13Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 5.8% to US$4.23. The fair value is estimated to be US$3.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.8% over the last 3 years. Earnings per share has declined by 7.4%.Board Change • Jan 29No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Nov 01No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.059 in 2Q 2022)Second quarter 2023 results: EPS: US$0.04 (down from US$0.059 in 2Q 2022). Revenue: US$10.9m (down 2.7% from 2Q 2022). Net income: US$1.67m (down 28% from 2Q 2022). Profit margin: 15% (down from 21% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.Upcoming Dividend • Apr 05Upcoming dividend of US$0.10 per share at 2.4% yieldEligible shareholders must have bought the stock before 12 April 2023. Payment date: 11 June 2023. Payout ratio is a comfortable 20% but the company is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.7%).Board Change • Nov 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 14Second quarter 2022 earnings released: EPS: US$0.063 (vs US$0.13 in 2Q 2021)Second quarter 2022 results: EPS: US$0.063 (down from US$0.13 in 2Q 2021). Revenue: US$11.2m (down 16% from 2Q 2021). Net income: US$2.30m (down 53% from 2Q 2021). Profit margin: 21% (down from 37% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year and the company’s share price has also increased by 18% per year.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Apr 14Upcoming dividend of US$0.10 per shareEligible shareholders must have bought the stock before 21 April 2022. Payment date: 19 June 2022. Payout ratio is a comfortable 24% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (5.5%). Higher than average of industry peers (1.7%).Reported Earnings • Feb 21Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$45.5m (up 27% from FY 2020). Net income: US$12.1m (up 64% from FY 2020). Profit margin: 27% (up from 21% in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 6% per year.Board Change • Feb 21No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Feb 18Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$45.5m (up 27% from FY 2020). Net income: US$12.1m (up 64% from FY 2020). Profit margin: 27% (up from 21% in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 4% per year.Reported Earnings • Jun 05First quarter 2021 earnings released: EPS US$0.05 (vs US$0.093 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$7.58m (down 9.9% from 1Q 2020). Net income: US$908.0k (down 50% from 1Q 2020). Profit margin: 12% (down from 22% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.収支内訳Birzeit Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史PLSE:BPC 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 2649137031 Dec 2548127030 Sep 2547136030 Jun 2546135031 Mar 254285031 Dec 244156030 Sep 243847030 Jun 244037031 Mar 244238031 Dec 234368030 Sep 234467030 Jun 234567031 Mar 234577031 Dec 224787030 Sep 2247108030 Jun 2248128031 Mar 2250147031 Dec 2145127030 Sep 2143117030 Jun 2140107031 Mar 213577031 Dec 203677030 Sep 203587030 Jun 203588031 Mar 203587031 Dec 1935107030 Sep 193387030 Jun 193276031 Mar 193586031 Dec 183686030 Sep 1835106030 Jun 1834106031 Mar 1833116031 Dec 1733116030 Sep 173486030 Jun 173496031 Mar 173486031 Dec 163285030 Sep 163065030 Jun 162855031 Mar 162855031 Dec 152655030 Sep 1527550質の高い収益: BPCは 高品質の収益 を持っています。利益率の向上: BPCの現在の純利益率 (25.6%)は、昨年(19%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: BPCの収益は過去 5 年間で年間1.1%減少しました。成長の加速: BPCの過去 1 年間の収益成長率 ( 58.2% ) は、5 年間の平均 ( 年間-1.1%を上回っています。収益対業界: BPCの過去 1 年間の収益成長率 ( 58.2% ) はPharmaceuticals業界8.8%を上回りました。株主資本利益率高いROE: BPCの 自己資本利益率 ( 11% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/18 23:19終値2026/07/16 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Birzeit Pharmaceuticals Company 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: US$0.038 (vs US$0.04 in 2Q 2023)Second quarter 2024 results: EPS: US$0.038 (down from US$0.04 in 2Q 2023). Revenue: US$8.36m (down 23% from 2Q 2023). Net income: US$1.48m (down 11% from 2Q 2023). Profit margin: 18% (up from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
Reported Earnings • Jun 13First quarter 2024 earnings released: US$0.04 loss per share (vs US$0.046 profit in 1Q 2023)First quarter 2024 results: US$0.04 loss per share (down from US$0.046 profit in 1Q 2023). Revenue: US$9.07m (down 11% from 1Q 2023). Net loss: US$1.44m (down 181% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 28Full year 2023 earnings released: EPS: US$0.16 (vs US$0.20 in FY 2022)Full year 2023 results: EPS: US$0.16 (down from US$0.20 in FY 2022). Revenue: US$43.1m (down 8.3% from FY 2022). Net income: US$6.12m (down 23% from FY 2022). Profit margin: 14% (down from 17% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.059 in 2Q 2022)Second quarter 2023 results: EPS: US$0.04 (down from US$0.059 in 2Q 2022). Revenue: US$10.9m (down 2.7% from 2Q 2022). Net income: US$1.67m (down 28% from 2Q 2022). Profit margin: 15% (down from 21% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 14Second quarter 2022 earnings released: EPS: US$0.063 (vs US$0.13 in 2Q 2021)Second quarter 2022 results: EPS: US$0.063 (down from US$0.13 in 2Q 2021). Revenue: US$11.2m (down 16% from 2Q 2021). Net income: US$2.30m (down 53% from 2Q 2021). Profit margin: 21% (down from 37% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year and the company’s share price has also increased by 18% per year.
Reported Earnings • Feb 21Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$45.5m (up 27% from FY 2020). Net income: US$12.1m (up 64% from FY 2020). Profit margin: 27% (up from 21% in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 6% per year.
Board Change • Jun 02No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 5 highly experienced directors. No independent directors (8 non-independent directors). Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 5 highly experienced directors. No independent directors (8 non-independent directors). Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 10+ 1 more updateBirzeit Pharmaceuticals Company announces Annual dividend, payable on July 15, 2026Birzeit Pharmaceuticals Company announced Annual dividend of USD 0.0500 per share payable on July 15, 2026, ex-date on May 06, 2026 and record date on May 07, 2026.
Board Change • Jun 10No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 25Birzeit Pharmaceuticals Company announces Annual dividend, payable on May 15, 2025Birzeit Pharmaceuticals Company announced Annual dividend of USD 0.0500 per share payable on May 15, 2025, ex-date on April 23, 2025 and record date on April 24, 2025.
Board Change • Apr 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 09Birzeit Pharmaceuticals Company, Annual General Meeting, Apr 22, 2025Birzeit Pharmaceuticals Company, Annual General Meeting, Apr 22, 2025. Location: ramallah Palestinian Authority
Board Change • Feb 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Oct 29New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.7% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.8% net profit margin).
Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: US$0.038 (vs US$0.04 in 2Q 2023)Second quarter 2024 results: EPS: US$0.038 (down from US$0.04 in 2Q 2023). Revenue: US$8.36m (down 23% from 2Q 2023). Net income: US$1.48m (down 11% from 2Q 2023). Profit margin: 18% (up from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
New Risk • Jun 13New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 39% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (4.9% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.9% net profit margin).
Reported Earnings • Jun 13First quarter 2024 earnings released: US$0.04 loss per share (vs US$0.046 profit in 1Q 2023)First quarter 2024 results: US$0.04 loss per share (down from US$0.046 profit in 1Q 2023). Revenue: US$9.07m (down 11% from 1Q 2023). Net loss: US$1.44m (down 181% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
New Risk • Jun 11New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.0% average weekly change).
Reported Earnings • Feb 28Full year 2023 earnings released: EPS: US$0.16 (vs US$0.20 in FY 2022)Full year 2023 results: EPS: US$0.16 (down from US$0.20 in FY 2022). Revenue: US$43.1m (down 8.3% from FY 2022). Net income: US$6.12m (down 23% from FY 2022). Profit margin: 14% (down from 17% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
Buy Or Sell Opportunity • Feb 13Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 5.8% to US$4.23. The fair value is estimated to be US$3.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.8% over the last 3 years. Earnings per share has declined by 7.4%.
Board Change • Jan 29No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Nov 01No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.059 in 2Q 2022)Second quarter 2023 results: EPS: US$0.04 (down from US$0.059 in 2Q 2022). Revenue: US$10.9m (down 2.7% from 2Q 2022). Net income: US$1.67m (down 28% from 2Q 2022). Profit margin: 15% (down from 21% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
Upcoming Dividend • Apr 05Upcoming dividend of US$0.10 per share at 2.4% yieldEligible shareholders must have bought the stock before 12 April 2023. Payment date: 11 June 2023. Payout ratio is a comfortable 20% but the company is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.7%).
Board Change • Nov 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 14Second quarter 2022 earnings released: EPS: US$0.063 (vs US$0.13 in 2Q 2021)Second quarter 2022 results: EPS: US$0.063 (down from US$0.13 in 2Q 2021). Revenue: US$11.2m (down 16% from 2Q 2021). Net income: US$2.30m (down 53% from 2Q 2021). Profit margin: 21% (down from 37% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year and the company’s share price has also increased by 18% per year.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Apr 14Upcoming dividend of US$0.10 per shareEligible shareholders must have bought the stock before 21 April 2022. Payment date: 19 June 2022. Payout ratio is a comfortable 24% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (5.5%). Higher than average of industry peers (1.7%).
Reported Earnings • Feb 21Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$45.5m (up 27% from FY 2020). Net income: US$12.1m (up 64% from FY 2020). Profit margin: 27% (up from 21% in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 6% per year.
Board Change • Feb 21No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 18Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$45.5m (up 27% from FY 2020). Net income: US$12.1m (up 64% from FY 2020). Profit margin: 27% (up from 21% in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 4% per year.
Reported Earnings • Jun 05First quarter 2021 earnings released: EPS US$0.05 (vs US$0.093 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$7.58m (down 9.9% from 1Q 2020). Net income: US$908.0k (down 50% from 1Q 2020). Profit margin: 12% (down from 22% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.